Alector, Inc. reported a net loss of $40.471 million for the three months ended March 31, 2025, compared to a net loss of $36.079 million for the same period in 2024. Collaboration revenue decreased significantly from $15.893 million in Q1 2024 to $3.674 million in Q1 2025. The company's cash, cash equivalents, and marketable securities totaled $354.6 million as of March 31, 2025, which is anticipated to provide runway into the second half of 2027.

Alector reported a strong fourth quarter in 2024, with collaboration revenue significantly increasing to $54.2 million from $15.2 million in the same period last year. The company also reduced its net loss to $2.1 million, or $0.02 per share, compared to a net loss of $41.4 million, or $0.49 per share, in Q4 2023. Cash, cash equivalents, and investments totaled $413.4 million, providing a runway through 2026.

Alector reported a net loss of $42.2 million, or $0.43 per share, for the quarter ended September 30, 2024. As of September 30, 2024, Alector’s cash, cash equivalents, and investments totaled $457.2 million, which is expected to fund operations through 2026.

Alector reported a net loss of $38.7 million for Q2 2024, with collaboration revenue of $15.1 million. The company's cash, cash equivalents, and investments totaled $503.3 million, expected to fund operations through 2026. Key clinical trials for AL002 and latozinemab are progressing, with potential data readouts and regulatory interactions anticipated.

Alector reported a net loss of $36.1 million, or $0.38 per share, for the quarter ended March 31, 2024. As of March 31, 2024, Alector’s cash, cash equivalents and investments totaled $562.1 million, providing runway through 2026.

Alector reported a net loss of $41.4 million for the quarter ended December 31, 2023, with collaboration revenue of $15.2 million. The company's cash, cash equivalents, and investments totaled $548.9 million as of December 31, 2023, which is anticipated to provide runway through 2026 after a January 2024 equity offering.

Alector reported a net loss of $44.5 million, or $0.53 per share, for the quarter ended September 30, 2023. As of September 30, 2023, Alector’s cash, cash equivalents and investments totaled $588.9 million, which is expected to fund operations through 2025.

Alector reported a net income of $1.4 million for the quarter ended June 30, 2023. The company's cash, cash equivalents, and investments totaled $630.0 million as of June 30, 2023, which is expected to fund operations through 2025. Collaboration revenue for the quarter was $56.2 million.

Alector reported a net loss of $45.9 million, or $0.55 per share, for the quarter ended March 31, 2023. As of March 31, 2023, cash, cash equivalents, and investments were $669.3 million. The company expects this to be sufficient to fund operations through 2025.

Alector reported Q4 2022 collaboration revenue of $14.4 million and a net loss of $52.4 million, with cash, cash equivalents, and investments totaling $712.9 million, expected to fund operations through 2025.

Alector reported a net loss of $46.1 million for the third quarter of 2022, with cash, cash equivalents, and investments totaling $758.3 million as of September 30, 2022, expected to fund operations through 2024. The company also progressed enrollment in clinical trials for latozinemab (AL001) and AL002, and initiated a Phase 1 trial for AL044.

Alector reported a net income of $9.9 million for the quarter ended June 30, 2022, compared to a net loss of $55.1 million for the same period in 2021. The company's cash, cash equivalents, and investments totaled $808.9 million as of June 30, 2022, which is expected to fund operations into H2 2024.

Alector reported a net loss of $44.6 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $868.6 million as of March 31, 2022, expected to fund operations into mid-2024. Significant progress was made in clinical trials, particularly with latozinemab in FTD-C9orf72 patients.

Alector reported Q4 2021 collaboration revenue of $14.0 million compared to $4.9 million for the same period in 2020. The company's cash, cash equivalents, and investments totaled $735.3 million as of December 31, 2021. Alector anticipates existing funds will support operations into mid-2024.

Alector reported collaboration revenue of $182.4 million, primarily driven by the recognition of $179.8 million from the GSK collaboration. Net income for the quarter was $126.6 million, or $1.56 per share, and cash, cash equivalents, and marketable securities totaled $777.9 million as of September 30, 2021.

Alector's Q2 2021 saw a collaboration with GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, along with encouraging Phase 2 data for AL001 in FTD-GRN. The company's cash, cash equivalents and investments totaled $319.6 million as of June 30, 2021.

Alector reported a collaboration revenue of $4.1 million for the quarter ended March 31, 2021, and a net loss of $52.2 million. The company's cash, cash equivalents, and marketable securities were $362.7 million as of March 31, 2021.

Alector reported collaboration revenue of $4.9 million for the quarter ended December 31, 2020, compared to $6.0 million for the same period in 2019. The company's net loss was $52.2 million, compared to a net loss of $30.5 million for the same period in 2019. Cash, cash equivalents, and marketable securities were $413.3 million as of December 31, 2020.

Alector reported a net loss of $52.7 million for the quarter ended September 30, 2020, with $461.7 million in cash and investments. Collaboration revenue was $5.9 million, and the company is advancing its clinical programs, including the initiation of a Phase 3 trial for AL001.

Alector reported collaboration revenue of $3.2 million, research and development expenses of $34.1 million, general and administrative expenses of $15.7 million, and a net loss of $45.3 million for the second quarter ended June 30, 2020. The company's cash, cash equivalents, and marketable securities were $503.6 million as of June 30, 2020.

Alector reported collaboration revenue of $7.2 million and a net loss of $40.0 million for the quarter ended March 31, 2020. The company's cash, cash equivalents, and marketable securities were $548.5 million as of March 31, 2020.

Alector reported a net loss of $30.5 million for the fourth quarter ended December 31, 2019, compared to a net loss of $17.4 million for the same period in 2018. Collaboration revenue for the quarter was $6.0 million, compared to $9.1 million for the same period in 2018. Cash, cash equivalents, and marketable securities were $353.1 million as of December 31, 2019.